Achieve Life Sciences appoints Benjamin Halladay CFO effective Oct. 5, 2026; Mark Oki steps down

ACHIEVE LIFE SCIENCES, INC.

Benjamin Halladay appointed CFO and principal financial officer effective Oct. 5, 2026; he was most recently CFO of Esperion Therapeutics from Nov. 2022 to Sept. 2026.
Halladay's compensation includes a $525,000 annual base salary, a discretionary bonus up to 40% of salary, 200,000 stock options and 200,000 RSUs.
Mark Oki stepped down as CFO effective Oct. 5, 2026; the company said his departure was not due to disagreement over financial statements or disclosures.
Halladay severance: nine months of base salary, or 12 months plus prorated bonus and accelerated option/RSU vesting if tied to a change in control.
Oki will receive severance under his Executive Employment Agreement dated Dec. 5, 2024, filed as Ex. 10.19 to the company's 2024 Form 10-K.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.